Filing Details

Accession Number:
0000904454-18-000697
Form Type:
4/A
Zero Holdings:
No
Publication Time:
2018-11-05 10:05:53
Reporting Period:
2018-10-30
Accepted Time:
2018-11-05 10:05:53
Original Submission Date:
2018-11-01
SEC Url:
Form 4 Filing
Issuer
Cik Name Symbol Sector (SIC) IRS No
1399529 Dicerna Pharmaceuticals Inc DRNA () 4/A
Insiders
Cik Name Reported Address Insider Title Director Officer Large Shareholder Other
1354718 K Brian Halak C/O Domain Associates, Llc
202 Carnegie Center, Suite 104
Princeton NJ 08540
No No Yes No
Reported Non-Derivative Transactions
Sec. Name Acquisiton - Disposition Date Amount Price Remaning Holdings Equity Swap Involved Form Type Code Nature of Ownership Explanation
Common Stock Disposition 2018-10-30 152,364 $13.68 3,327,511 No 4 S Indirect By Domain Partners VIII, L.P.
Common Stock Disposition 2018-10-30 1,136 $13.68 24,674 No 4 S Indirect By DP VIII Associates, L.P.
Common Stock Disposition 2018-10-30 90,918 $14.31 3,236,593 No 4 S Indirect By Domain Partners VIII, L.P.
Common Stock Disposition 2018-10-30 678 $14.31 23,996 No 4 S Indirect By DP VIII Associates, L.P.
Common Stock Disposition 2018-10-31 128,670 $13.60 3,107,923 No 4 S Indirect By Domain Partners VIII, L.P.
Common Stock Disposition 2018-10-31 959 $13.60 23,037 No 4 S Indirect By DP VIII Associates, L.P.
Common Stock Disposition 2018-11-01 188,867 $13.37 2,919,056 No 4 S Indirect By Domain Partners VIII, L.P.
Common Stock Disposition 2018-11-01 1,408 $13.37 21,629 No 4 S Indirect By DP VIII Associates, L.P.
Equity Swap Involved Form Type Code Nature of Ownership Explanation
No 4 S Indirect By Domain Partners VIII, L.P.
No 4 S Indirect By DP VIII Associates, L.P.
No 4 S Indirect By Domain Partners VIII, L.P.
No 4 S Indirect By DP VIII Associates, L.P.
No 4 S Indirect By Domain Partners VIII, L.P.
No 4 S Indirect By DP VIII Associates, L.P.
No 4 S Indirect By Domain Partners VIII, L.P.
No 4 S Indirect By DP VIII Associates, L.P.
Footnotes
  1. The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $13.26 to $14.2499. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in this footnote.
  2. The Reporting Person is a Managing Member of One Palmer Square Associates VIII, LLC, which is the sole general partner of Domain Partners VIII, L.P. and DP VIII Associates, L.P. Pursuant to Instruction (4)(b)(iv) of Form 4, the Reporting Person has elected to report as indirectly beneficially owned the entire number of securities beneficially owned by each such entity. The Reporting Person disclaims beneficial ownership of any securities, and any proceeds thereof, that exceed his pecuniary interest therein and/or that are not actually distributed to him.
  3. The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $14.25 to $14.46. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in this footnote.
  4. The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $13.25 to $14.19. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in this footnote.
  5. The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $13.04 to $13.59. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in this footnote.
  6. This amendment is being filed solely to correct a typographical error in this share number as reported in the Form 4 filed on November 1, 2018.